Displaying drugs 14651 - 14675 of 14817 in total
BMS-394136
BMS-394136 has been used in trials studying the diagnostic of Heart Diseases.
Investigational
R411
R411 is a non-steroid oral medicine for the treatment of asthma. It is not immunosuppressive, but blocks the activation and recruitment of cells involved in respiratory inflammation. It is a dual-acting competitive integrin antagonist (as compared to previously developed single integrin antagonists or SIAs) that prevents binding of V-CAM1 to...
Investigational
Matched Description: … It is not immunosuppressive, but blocks the activation and recruitment of cells involved in respiratory …
N-(3-cyclopropyl-1H-pyrazol-5-yl)-2-(2-naphthyl)acetamide
N-(3-cyclopropyl-1H-pyrazol-5-yl)-2-(2-naphthyl)acetamide is a solid. This compound belongs to the naphthalenes. These are compounds containing a naphthalene moiety, which consists of two fused benzene rings. The proteins that N-(3-cyclopropyl-1H-pyrazol-5-yl)-2-(2-naphthyl)acetamide targets include cyclin-A2 and cyclin-dependent kinase 2.
Experimental
Matched Description: … The proteins that N-(3-cyclopropyl-1H-pyrazol-5-yl)-2-(2-naphthyl)acetamide targets include cyclin-A2 and …
NV-18
NV-18 is a product of the Novogen diphenolic synthetic analogue program that is creating drugs with diverse activities against specific types of cancer. Like phenoxodiol, NV-18 is broadly effective in the laboratory against almost all human cancer types, but NV-18 is distinctive in showing particular potency against melanoma and cholangiocarcinoma...
Investigational
Matched Description: … almost all human cancer types, but NV-18 is distinctive in showing particular potency against melanoma and …
Sirna-027
Sirna-027 is a chemically modified short interfering RNA(siRNA) targeting Vascular Endothelial Growth Factor Receptor-1(VEGFR-1). VEGFR-1 is a key component of the clinically validated vascular endothelial growth factor (VEGF) pathway. Sirna-027 is developed by Sirna Therapeutics and is under the phase I of clinical trails. It is used to treat Macular...
Investigational
Matched Description: … Sirna-027 is developed by Sirna Therapeutics and is under the phase I of clinical trails. …
L-aminocarnityl-succinyl-leucyl-argininal-diethylacetal
C-101, also called Myodur, is developed for the treatment of Duchenne’s muscular dystrophy (DMD) which is a morbid genetic disease that can lead to death in late adolescence due to accelerated skeletal muscle breakdown. C-101 includes a carnitine carrier molecule and a leupeptin analogue, a known calpain inhibitor. Calpain is...
Investigational
Matched Description: … C-101 includes a carnitine carrier molecule and a leupeptin analogue, a known calpain inhibitor. …
BW-A 58C
BW-A 58C, also known as 2-(4-tert-butylcyclohexyl)-3-hydroxy-1,4-naphthoquinone, is an experimental naphthoquinone antimalarial drug which undergoes extensive alkyl hydroxylation to a single t-butylhydroxy metabolite in man in vivo and also in human liver microsomes, where this is catalysed primarily by a 54 kDa CYP2C9 form of cytochrome P450, P450hB20-27.
Experimental
Matched Description: … which undergoes extensive alkyl hydroxylation to a single t-butylhydroxy metabolite in man in vivo and …
Deracoxib
Deracoxib is a non-steroidal anti-inflammatory drug of the coxib class, used in veterinary medicine to treat osteoarthritis in dogs. It is sold in tablets, which have added beefy flavour to increase palatability. Deramaxx received FDA approval in August 2002 for "the control of post operative pain and inflammation associated with...
Vet approved
Matched Description: … Deramaxx received FDA approval in August 2002 for "the control of post operative pain and inflammation …
2-(4-HYDROXY-3-NITROPHENYL)ACETIC ACID
Experimental
Rivoglitazone
Rivoglitazone (INN) is a thiazolidinedione undergoing research for use in the treatment of type 2 diabetes. It is being developed by Daiichi Sankyo Co.
Experimental
Investigational
4SC-203
4SC-203 has been used in trials studying the treatment of Acute Myeloid Leukemia.
Investigational
ND1251
ND1251 is an orally active phosphodiesterase-4 (PDE4) inhibitor, a mechanism clinically proven to play a role in alleviating symptoms of depression. ND1251 is a very potent compound with a large safety margin. ND1251 may also have applications in other disorders, such as Alzheimer's disease, mild cognitive impairment, multiple sclerosis and...
Investigational
Matched Description: … applications in other disorders, such as Alzheimer's disease, mild cognitive impairment, multiple sclerosis and …
Sorbinil
Experimental
Investigational
Displaying drugs 14651 - 14675 of 14817 in total